



SHUKRA

PHARMACEUTICALS LTD.

29th June, 2021

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 29th June, 2021 at 11:00 a.m. and concluded at 06:00 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter and year ended on 31st March, 2021.
2. Appointment of CS Rupal Patel, Practicing Company Secretary, as Secretarial Auditor of the Company for the F.Y. 2020-21.
3. Reviewed business of the Company.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For, Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
DIN: 08316893

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

29th June, 2021

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Scrip Code: 531529

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to above, we hereby state that the statutory Auditor of the Company M/s. B. J. Trivedi & Associates have issued an Audit Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the quarter and year ended 31st March, 2021 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For, Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
DIN: 08316893

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

PART I

Financial results by company

(Rs. in Lakhs)

Statement of Standalone Audited Results for the Quarter and Year Ended 31-03-2021

S/N	Particulars (Refer Notes Below)	Quarter Ended			Year Ended	
		(31-03-2021)	(31-12-2020)	(31-03-2020)	(31-03-2021)	(31-03-2020)
		(Audited) (Refer Note 4)	(Unaudited)	(Audited) (Refer Note 4)	(Audited)	(Audited)
1	Revenue from Operation	426.19	414.93	403.58	1,119.61	1,184.60
	Other income	(15.25)	27.01	0.71	35.62	0.97
	Total Revenue (I + II)	410.94	441.94	404.29	1,155.23	1,185.57
2	Expenses					
	(a) Cost of materials consumed	176.13	76.26	25.46	294.70	332.82
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(38.07)	87.11	13.82	(19.26)	(32.69)
	(d) Employee benefits expense	163.49	94.38	138.93	406.74	440.04
	(e) Finance Cost	3.00	0.01	0.14	3.33	0.21
	(f) Depreciation and amortisation expense	38.74	36.21	62.07	147.37	147.82
	(g) Other expenses	79.01	118.39	219.64	293.04	290.41
	Total expenses	422.30	412.36	460.06	1,125.92	1,178.61
3	Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	(11.36)	29.58	(55.77)	29.31	6.96
4	Exceptional items expenses	19.53	0.00	(10.11)	19.53	(10.11)
5	Profit / (Loss) before extraordinary items and tax (V - VI)	(30.89)	29.58	(45.66)	9.78	17.07
6	Tax expense - Provision for taxation					
	Current Tax - Provision for taxation	(7.70)	8.88	(18.82)	4.50	0.00
	Deferred Tax	1.90		13.51	1.90	13.51
7	Net Profit / (Loss) for the period	(23.19)	20.70	(26.84)	3.38	3.56
8	Other Comprehensive Income/(Loss) (net of tax)	0.00	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) for the period	(23.19)	20.70	(26.84)	3.38	3.56
10	Paid up Equity Share Capital (Face value of Rs. 10/- each)	156.57	156.57	156.57	156.57	156.57
11	Earnings per equity share:					
	(1) Basic	(1.48)	1.32	(1.71)	0.22	0.23
	(2) Diluted	(1.48)	1.32	(1.71)	0.22	0.23

CIN : L24231GJ1993PLC019079

[Signature]

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. * 02764-286317



SHUKRA

PHARMACEUTICALS LTD.

Notes:

- 1 The Audited Financial Results for the Quarter and Year ended 31st March, 2021, have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors at their respective meetings held on 29th June, 2021. The Statutory Auditors of the Company have carried out an audit for the year ended 31st March, 2021 and the Statutory Auditors have expressed an unmodified audit opinion thereon.
- 2 The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- 3 The Audited Financial Results of the Company are available on Company's website i.e. 29th June, 2021 and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 4 The figures of the quarter ended 31st March, 2021 are the balancing figures between Audited Figures in respect of the Full Financial year and the published year to date figures up to third quarter of the relevant financial year.
- 5 The COVID19 pandemic has disrupted various business operations due to lockdown and other emergency measures imposed by the governments. The operations of the Company were impacted briefly, due to shutdown of sites and offices following nationwide lockdown, as appearing in the results for the period and to that extent, numbers are not comparable. The Company continues with its operations in phased manner in line with directives from the authorities. The Company has made detailed assessment of its liquidity positions and business operations and its possible effect on the carrying value of assets including that of second wave. The Company does not expect significant impact on its operations and recoverability of value of its assets based on current indicators of future economic conditions. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor any material changes to future economic condition and its impact, if any.
- 6 Figures relating to the previous year / period have been regrouped / rearranged, wherever necessary, to make them comparable with those of the current year / period.
- 7 This communication is in compliance with the SEBI (Listing Obligations & Requirement) Regulations, 2015

Date: 29/06/2021

Place: AHMEDABAD

By Order of the Board of Directors

For, Shukra Pharmaceuticals Limited

(Formerly known as "Relish Pharmaceuticals Limited")



Bhoomiben Patel (Director)

DIN: 08316893

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317



SHUKRA

PHARMACEUTICALS LTD.

Stamenet Of Assets and Liability			(Rs. In Lacs)
Particulars	Standalone		
	As at 31st March, 2021	As at 31st March, 2020	
A) Assets	Audited	Audited	
Non Current Assets			
Property Plant and Equipement	1,769.15	1,737.91	
Capital Work In Progress	166.17	166.17	
Other Intengible Assets			
Intengible assets under Development			
Financial Assets			
i) Investment	19.48	5.23	
ii) Loan	0.00	0.00	
iii) Other Financial Assets	0.00	0.00	
Deferred Tax Assets (net)	0.00	0.00	
Other non current Assets	0.00	0.00	
Total Non Current Assets	1,954.80	1,909.31	
Current Assets			
Inventories	169.65	138.66	
Financial Assets			
i) Trade Receivable	890.29	795.12	
ii) Cash and Cash Equivalents	41.02	12.64	
iii) Bank Balance other than (ii)above	0.00	0.00	
iv) Other Financial Assets	342.89	474.14	
Other Current Assets	14.43	24.64	
Total Curent Assets	1,458.28	1,445.20	
Total Assets	3,413.08	3,354.51	
B) Equity and Liabilities			
Equity Share Capital	156.57	156.57	
Other Equity	1,400.92	1,384.55	
Total Equity	1,557.49	1,541.12	
Non Current Liabilities			
Financial Liabilities			
i) Borrowings	977.05	805.18	
Defered Tax Liabilities	309.63	309.63	
Total Non Current Liabilities	2,844.17	2,655.93	
Current Liabilities			
Financial Liabilities			
i) Borrowings	0.00	0.00	
ii) Trade Payables	484.31	646.13	
iii) Other Financial Liabilities	0.00	0.00	
Provisions	84.60	52.45	
Other Current Liabilities	0.00	0.00	
Total Current Liabilities	568.91	698.58	
Total Equity and Liabilities	3,413.08	3,354.51	

Date: 29/06/2021
Place: AHMEDABAD

By Order of the Board of Directors
For, Shukra Pharmaceuticals Limited
(Formerly known as "Rishabh Pharmaceuticals Limited")



Bhoomiben Patel (Director)

CIN : L24231GJ1993PLC019079

DIN: 08316893

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317



SHUKRA

PHARMACEUTICALS LTD.

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2021

Particulars	Standalone	
	For the period ended on 31-03-2021	For the period ended on 31-03-2020
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	9.78	17.07
Adjustments for:		
Depreciation		
Preliminary Exps. Written off	147.37	147.82
Finance Cost	5.29	5.29
	3.33	0.21
Operating Profit before Working Capital Changes	165.77	170.39
Movements in Working Capital :		
Decrease / (Increase) in Inventories	(30.99)	(111.59)
Decrease / (Increase) in Sundry Debtors	(95.17)	(260.49)
Decrease / (Increase) in Loans and Advances	0.00	0.00
Decrease / (Increase) in Current Assets	141.46	21.97
Decrease / (Increase) in Non Current Assets	(14.25)	(0.06)
(Decrease) / Increase in Trade Payables	(161.82)	331.20
(Decrease) / Increase in Short Term Provisions	0.00	0.00
(Decrease) / Increase in Current Liabilities	0.00	0.00
(Decrease) / Increase in Other Current Liabilities	0.00	0.00
Cash (used in) / generated from operations	32.15	(32.29)
Direct Taxes Paid (net of refunds)	0.00	0.00
Net cash (used in) / generated from operating activities (A)	37.15	119.13
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Purchase) of Fixed Assets	(180.64)	(315.09)
Sale / Disposal of Fixed Assets	0.00	0.00
Interest Received	0.00	0.00
Borrowing	0.00	0.00
Profit on sale of Investment / Assets	0.00	0.00
Net cash (used in) / generated from investing activities (B)	(180.64)	(315.09)
C. CASH FLOW FROM FINANCING ACTIVITIES		
(Repayment) / Proceeds From Long Term Borrowings	171.87	199.49
(Repayment) / Proceeds From Short Term Borrowings	0.00	0.00
Repayment / (Proceeds) From Long Term Loans & Advances	0.00	0.00
Proceeds from Issue of Shares	0.00	0.00
Interest Expense	0.00	0.00
Dividend	0.00	0.00
Dividend Distribution Tax	0.00	0.00
Net cash (used in) / generated from financing activities (C)	171.87	199.49
D. NET INCREASE IN CASH AND CASH EQUIVALENTS (D)=(A+B+C)	28.38	3.53
Cash and cash equivalents at the beginning of the year	12.64	24.85
Cash and cash equivalents at the end of the year	41.02	28.38
Components of cash and cash equivalents		
Cash and cheques on hand		
With Scheduled Banks	0.00	0.00
- in Current Account	0.00	0.00
- in Term Deposit Accounts	0.00	0.00
	0.00	0.00

Date: 29/06/2021
Place: AHMEDABAD

CIN : L24231GJ1993PLC019079

By Order of the Board of Directors
For, Shukra Pharmaceuticals Limited
(Formerly known as "Reliance Pharmaceuticals Limited")



Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bhagdev, Ahmedabad-380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar 382721, Gujarat, India, Ph. : 02764-286317



Auditor's Report on Quarterly Financial Results and year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

To,
The Board of Directors,
Shukra Pharmaceuticals Limited,
Ahmedabad

Report on audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Jyot International Marketing Limited (the company) for the Quarter ended 31st March, 2021 and the year to date results for the period from 01st April, 2020 to 31st March, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended 31st March, 2021 as well as the year to date results for the period from 01st April, 2020 to 31st March, 2021

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered



Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis Matter

We draw your attention to Note 5 to the Financial Results which explains the management's assessment of the financial impact due to the lock-down and other restrictions and conditions related to the COVID-19 pandemic situation, for which a definitive assessment of the impact in the subsequent period is highly dependent upon circumstances as they evolve. Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Date: 29/06/2021
Place: Ahmedabad



For, M/s. B. J. Trivedi & Associates,
Chartered Accountants
Firm Reg. No.: 111042W

Bharat Trivedi
Proprietor
Membership No.: 039595
UDIN: 21039595AAAADT3738